Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.65 |
| ▸ | EGFR | P00533 | 4/20 | 0.65 |
| ▸ | ABL1 | P00519 | 4/20 | 0.63 |
| ▸ | ABL2 | P42684 | 3/20 | 0.63 |
| ▸ | LCK | P06239 | 3/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ADK | P55263 | 9/20 | 0.50 |
| ▸ | FGR | P09769 | 1/20 | 0.49 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.49 |
| ▸ | TXK | P42681 | 1/20 | 0.49 |
| ▸ | FRK | P42685 | 1/20 | 0.49 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29999242 | 1.00 | SRC (0.65) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL27088114 | 1.00 | SRC (0.65) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL30767877 | 0.92 | SRC (0.57) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL19743649 | 0.92 | FGR (0.57) | SRCEGFRABL1ABL2LCK | |
| Hydrochloric Acid SCHEMBL29999025 | 0.91 | FGR (0.56) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL29999095 | 0.89 | MTOR (0.55) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL24650661 | 0.89 | MTOR (0.55) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL16237288 | 0.84 | SRC (0.59) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL15739516 | 0.84 | SRC (0.50) | SRCEGFRABL1ABL2LCK | |
| Tert-Butyl Formate SCHEMBL27080003 | 0.82 | SRC (0.51) | SRCEGFRABL1ABL2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| CN-115485281-B | FGFR and mutation inhibitor thereof, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4169922-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| CN-115485281-A | FGFR and mutation inhibitor thereof, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022033532-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
| WO-2022033532-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | FGFR3, FGFR1, FGFR4 | SRC 100/4885EGFR 115/4885ABL1 121/4885 |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | SRC 30/4885EGFR 8/4885ABL1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.